KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) FCF Margin (2017 - 2025)

Historic FCF Margin for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to 13.53%.

  • Amneal Pharmaceuticals' FCF Margin fell 42400.0% to 13.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 9.01%, marking a year-over-year decrease of 9300.0%. This contributed to the annual value of 8.7% for FY2024, which is 39300.0% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its FCF Margin stood at 13.53% for Q3 2025, which was down 42400.0% from 8.42% recorded in Q2 2025.
  • Amneal Pharmaceuticals' FCF Margin's 5-year high stood at 27.65% during Q1 2021, with a 5-year trough of 23.34% in Q2 2022.
  • Moreover, its 5-year median value for FCF Margin was 11.25% (2023), whereas its average is 7.97%.
  • In the last 5 years, Amneal Pharmaceuticals' FCF Margin plummeted by -479000bps in 2021 and then soared by 261200bps in 2023.
  • Amneal Pharmaceuticals' FCF Margin (Quarter) stood at 8.52% in 2021, then tumbled by -167bps to 5.7% in 2022, then skyrocketed by 458bps to 20.42% in 2023, then crashed by -31bps to 14.09% in 2024, then decreased by -4bps to 13.53% in 2025.
  • Its FCF Margin was 13.53% in Q3 2025, compared to 8.42% in Q2 2025 and 0.83% in Q1 2025.